# Application of blinatumomab in adult acute B-lymphoblastic leukemia: a comprehensive strategy from remission induction to post-transplantation maintenance

## TL;DR

This paper reviews the use of blinatumomab in treating adult B-cell acute lymphoblastic leukemia, focusing on its role in achieving remission and supporting post-transplant care.

## Contribution

The paper provides a comprehensive strategy for using blinatumomab from remission induction to post-transplant maintenance in adult B-ALL.

## Key findings

- Blinatumomab improves remission rates in relapsed/refractory B-ALL patients.
- It helps bridge patients to allo-HSCT and supports post-transplant maintenance.
- The therapy effectively targets chemotherapy-resistant B-ALL cells.

## Abstract

异基因造血干细胞移植（allo-HSCT）是成人复发/难治性急性淋巴细胞白血病（ALL）的重要治疗选择之一，而实现完全缓解（CR）是allo-HSCT前的关键步骤。近年来研究表明，使用双特异性T细胞衔接器（BiTE）贝林妥欧单抗进行免疫治疗，可清除残留的化疗耐药B-ALL细胞，显著提高复发/难治性B-ALL患者及微小残留病阳性患者的缓解率，成功桥接至allo-HSCT，并为移植后复发防治和维持治疗提供了更多选择。本文就贝林妥欧单抗在成人B-ALL治疗中的应用策略进行综述。